Company intelligence / Profile preview

天台银康生物医药

Taizhou, Zhejiang, China

Ownership: Private
Development stage: Other

Overview

Tiantai Yinkang Biomedical Co., Ltd. is a Chinese biopharmaceutical company founded in 2017 and based in Tiantai, Zhejiang Province. The company focuses on the research, development, and commercialization of biological drugs, particularly fusion proteins for ophthalmic indications. Its lead candidate, IBI304 (a recombinant human VEGF receptor-Fc fusion protein), is currently in Phase 1 clinical development for the treatment of macular edema, including venous occlusive macular edema. Tiantai Yinkang has secured investments from notable partners, including Zhejiang Shengda Biopharmaceutical and Zhejiang Yinlun Machinery, to advance its pipeline.

Therapeutic areas: Ophthalmology
Modalities: Recombinant fusion proteinBiologic
Industry: Biotech

Partnerships

Innovent Biologics

Beyond the preview

Go deeper on 天台银康生物医药.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 天台银康生物医药.

Explore the full profile